5:35 PM
 | 
Dec 07, 2012
 |  BC Extra  |  Company News

FDA panel rebuffs Zohydro ER

FDA's Anesthetic and Analgesic Drug Products Advisory Committee voted 11-2 with one abstention against approval of Zohydro ER hydrocodone bitartrate from Zogenix Inc. (NASDAQ:ZGNX) to manage moderate to severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. The panel voted 8-5, with one abstention, that Zohydro ER was effective, but voted...

Read the full 285 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >